skip to the content

Untreated follicular NHL

MabThera-based therapy is the standard of care in FL, and clinical studies demonstrate that it is now possible to change the natural history of the disease and achieve prolonged survival.1–7

 

References

1. Marcus R, Imrie K, Belch A, et al. Blood 2005;105:1417–1423.

2. Marcus R, Solal-Celigny P, Imrie K, et al. Blood 2006;108:146a (Abstract 481).

3. Buske C, Hoster E, Dreyling M, et al. Blood 2006;108:1504–1508.

4. Foussard C, Mounier N, Van Hoof A, et al. J Clin Oncol 2006;24(Suppl. 18 Pt I):424s (Abstract 7508).

5. Herold M, Haas A, Srock S,et al. Blood 2006;108:147a (Abstract 484).

6. Hiddemann W, Knebba M, Dreyling M, et al. Blood 2005;106:3725–3732.

7. Salles GA, Foussard C, Nicolas M, et al. Blood 2004;104:49a–50a (Abstract 160).

MabThera plus chemotherapy first-line

MabThera plus chemotherapy significantly improves overall survival.

MabThera plus chemotherapy first-line

Your feedback is valuable to MabThera

Safety

Safety

MabThera has more than 10 years of clinical experience and more than 1,000,000 patients have been treated to date.

Find out more

Brief prescribing information

Brief prescribing information

Download the Brief Prescribing Information for MabThera.

Now for download

NHL subtypes

NHL subtypes

The WHO/REAL classification system is used worldwide for differentiation of NHL subtypes.

Learn more

MabThera product characteristics

MabThera product characteristics

Find out more about the characteristics of MabThera and how it is used in the treatment of non-Hodgkin's lymphoma.

Read more